Additionally, the negative correlation between APOC1 expression and PD-1/PD-L1 levels in human HCC samples suggests that manipulating ferroptosis pathways could further refine the responsiveness to immunotherapeutic agents. This evidence concerns the gene APOC1 and hepatocellular carcinoma.